Extracorporeal Photopheresis for Second-Line Treatment of Chronic Graft-versus-Host Diseases- Results from a Health Technology Assessment in Italy

Jun 1, 2015, 00:00 AM
10.1016/j.jval.2015.01.009
https://www.valueinhealthjournal.com/article/S1098-3015(15)00021-2/fulltext
Section Title : Comparative Effectiveness Research/HTA
Section Order : 13
First Page : 457

Objectives

To develop a comparative, cost-effectiveness, and budget impact analysis of Therakos online extracorporeal photopheresis (ECP) compared with the main alternatives used for the treatment of steroid-refractory/resistant chronic graft-versus-host disease (cGvHD) in Italy.

Methods

The current therapeutic pathway was identified by searching medical databases and from the results of a survey of practice in Italian clinical reference centers. A systematic review was performed to evaluate the efficacy and safety of second-line alternatives. Budget impact and cost-effectiveness analyses were performed from the Italian National Health Service perspective over a 7-year time horizon through the adaption of a Markov model. The following health states were considered: complete and partial response, stable disease, and progression. A discount rate of 3% was applied to costs and outcomes.

Results

The most common alternatives used in Italy for the management of steroid-refractory/resistant cGvHD were ECP, mycophenolate, pentostatin, and imatinib. The literature review highlighted that complete and partial responses are higher with ECP than with the alternatives while serious adverse events are less common. The economic analysis showed that Therakos online ECP represents the dominating alternative, in that it delivers greater benefit at a lower cost. In fact, according to the alternatives considered, cost saving ranged from €3237.09 to €19,903.51 per patient with 0.04 to 0.21 quality-adjusted life-year gained.

Conclusions

Therakos online ECP should be considered an effective, safe, and cost-effective alternative in steroid-refractory/resistant cGvHD. There is inequality in access, and a dedicated reimbursement tariff, however, should be introduced to overcome these barriers.

https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)00021-2&doi=10.1016/j.jval.2015.01.009
HEOR Topics :
  • Cost-comparison, Effectiveness, Utility, Benefit Analysis
  • Economic Evaluation
  • Specific Diseases & Conditions
  • Systemic Disorders/Conditions
Tags :
  • cost-effectiveness analysis
  • economic evaluation
  • graft-versus-host disease
  • Markov model
  • photopheresis
  • technology assessment
Regions :
  • Africa
  • Eastern and Central Europe
  • Middle East
  • Western Europe